Abstract
AbstractIn the HERS trial, hormone therapy did not reduce the risk of coronary events. In post hoc analyses, treatment was associated with early harm and late benefit. According to one hypothesis, a risk factor may well distinguish a susceptible subgroup with early events associated with hormone therapy from a nonsusceptible subgroup who benefit from hormone therapy. In simulation studies, it appeared that only a susceptibility factor with a low prevalence (3–5%) and a high risk ratio (13–25‐fold) can produce the pattern of risks seen in HERS. The number of candidate factors is likely to be small.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
